Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | iC9-CAR.B7-H3 T-cells |
| Trade Name | |
| Synonyms | iC9-CAR.B7-H3 T cells |
| Drug Descriptions |
iC9-CAR.B7-H3 T-cells are T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting B7-H3 (CD276) and an inducible caspase 9, which potentially induce killing of B7-H3 (CD276)-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2023;11). |
| DrugClasses | CD276 Immune Cell Therapy 10 |
| CAS Registry Number | NA |
| NCIT ID | C204924 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| iC9-CAR.B7-H3 T-cells | iC9-CAR.B7-H3 T-cells | 0 | 3 |